

## iPLEX<sup>®</sup> PGx 74 Panel

# Targeted Detection of Key Pharmacogenetic Markers

The iPLEX® PGx 74 Panel is a set of pre-designed assays that target the most relevant variants in 20 principal genes implicated in drug metabolism pathways. Combined with the accuracy and flexibility of the MassARRAY® System, identifying key biomarkers in pharmacogenetics is now easier and more cost effective than ever.

#### **INTRODUCTION**

Recent research has linked a number of genes, including CYP2C19, CYP2C9, CYP2D6, and VKORC1, with an individual's drug response.<sup>1-4</sup> Single nucleotide polymorphisms (SNP) and copy number variations (CNVs) in these genes have been shown to influence the rate of drug metabolism.<sup>5-7</sup> An extended panel of genes may help to guide clinical research for therapeutic treatment and response.<sup>8-9</sup>

Obtain relevant data for 69 SNPs/INDELs in 20 genes, plus 5 CNVs in CYP2D6.

Use flexible throughput formats to accommodate varying sample throughput.

Get robust data reporting with interactive visualization for results management.

### **GENES ANALYZED WITH iPLEX® PGx 74 PANEL**

ABCB1	DRD2
APOE	F2
COMT	F5
CYP1A2	GLP1R
CYP2B6	MTHFR
CYP2C19	OPRM1
CYP2C9	PNPLA5
CYP2D6	SLCO1B1
CYP3A4	SULT4A1
CYP3A5	VKORC1

For Research Use Only. Not for use in diagnostic procedures.

Agena Bioscience, Inc. 4755 Eastgate Mall San Diego, CA 92121 Phone: +1.858.882.2800 Order Desk: +1.858.202.9301 Order Desk Fax: +1.858.202.9220 **EU:** +49.40.899676.0 orderdesk@AgenaBio.com Web: agenabioscience.com

US: +1.877.4.GENOME

**AP:** +61.7.3088.1600

**CN:** +86.21.6427.0566

51-20105R1.0 0317

#### WORKFLOW

Each sample is subjected to targeted PCR amplification requiring as little as 10 ng genomic DNA for each multiplex, followed by primer extension with the iPLEX PGx 74 reagents. The extension products are dispensed onto a SpectroCHIP® Array and detected via mass spectrometry using the MassARRAY System. After the sample run, an automated software report provides diplotype, haplotype, and CNV calls in a single combined report. The report identifies CNV assays and calculates a relative copy number of 0, 1, 2, 3, or >4 copies with an associated confidence score.

#### THROUGHPUT

The iPLEX PGx 74 Panel contains multiplexed assays in 3 wells and can be run in 96-well format (32 samples per plate) or 384-well format (128 samples per plate), providing flexibility in sample throughput and batching requirements.

#### **ORDERING INFORMATION**

Order the iPLEX PGx 74 Panel and a complete iPLEX Pro Reagent Set for use on your MassARRAY System.

#### **INTERESTED IN LEARNING MORE?**

If you have questions about Agena Bioscience's products or services, or would like to place an order, please contact your local sales representative.

#### REFERENCES

- 1. Jaja C., et al. "Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients" *Genet Test Mol Biomarkers* (2016) 20(10):609-615.
- 2. Hirose T., et al. "Association of Pharmacokinetics and Pharmacogenomics with Safety and Efficacy of Gefitinib in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer" *Lung Cancer* (2016) 93:69–76
- Scott S. A., et al. "Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 update" *Clin Pharmacol Ther* (2013) 94(3):317-323
- 4. Wang L., et al. "Genomics and Drug Response" *N Engl J Med* (2011) 364:1144-1153
- 5. Brauch H., et al. "Pharmacogenomics of Tamoxifen Therapy" *Clin Chem* (2009) 55(10):1770-82
- Ingelman-Sundberg, Magnus, et al. "Influence of Cytochrome P450 Polymorphisms on Drug Therapies: Pharmacogenetic, Pharmacoepigenetic and Clinical Aspects" *Pharmacology & Therapeutics* (2007) 496-526
- Evans W.E. and Relling M.V. "Moving Towards Individualized Medicine with Pharmacogenomics" *Nature* (2004) 429(6990):464-468
- Goh L.L. et al., "Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation" *PLoS One* (2017) 12(1): e0169233
- Pratt V.M., et al. "Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes" J Mol Diagn (2016) 18(1):109-23